Historically, most patients with low-risk prostate cancer (clinical category T1c-T2a, prostate-specific antigen level <10 ng/mL, and Gleason 6 disease) were treated with radical prostatectomy, while radiotherapy-based treatment was the favored approach for high-risk localized prostate cancer. 
AS/WW to definitive therapy occurred within 1 year of diagnosis for reasons other than disease progression, the cases were coded as the definitive therapy used. Definitive therapy types were defined by SEER as either definitive radical prostatectomy or radiotherapy (including external-beam radiotherapy, brachytherapy, or any combination thereof); the positive predictive value and specificity of both variables are high.
Baseline characteristics, stratified by year of diagnosis, were summarized by descriptive statistics. Use of initial Results | Among 164 760 men, 20 879 (12.7%) had AS/WW management, 68 350 (41.5%) had radiotherapy, and 75 531 (45.8%) had radical prostatectomy. Men with diagnoses in 2015 (n = 25 140) compared with 2010 (n = 31 355) had significantly lower rates of low-risk disease (24.5% vs 34.2%), a higher median age (65 vs 64 years), and a higher median prostatespecific antigen level (6.7 vs 6.0 ng/mL) (all P < .05) (Table) .
In men with low-risk disease (n = 50 302), AS/WW use increased from 14.5% to 42.1% from 2010 to 2015 (P < .001 for trend), while radical prostatectomy decreased from 47.4% to 31.3% (P < .001 for trend) and radiotherapy from 38.0% to 26.6% (P < .001 for trend) (Figure, A) . In men with intermediate-risk disease (n = 81 836), AS/WW use increased from 5.8% to 9.6% from 2010 to 2015 (P < .001 for trend), while radical prostatectomy decreased from 51.8% to 50.6% (P = .004 for trend) and radiotherapy from 42.4% to 39.8% (P < .001 for trend) (Figure, B) . In men with high-risk disease (n = 32 622), AS/WW use remained stable (1.9% to 2.2%) from 2010 to 2015 (P = .08 for trend), while radical prostatectomy use increased from 38.0% to 42.8% (P < .001 for trend) and radiotherapy use decreased from 60.1% to 55.0% (P < .001 for trend) (Figure, C) .
Discussion | Use of AS/WW for men with low-risk localized prostate cancer increased from 2010 to 2015, becoming the most common management approach. Radical prostatectomy use declined among men with low-risk disease but increased among patients with higher-risk disease. Although increasing use of AS/WW for low-risk disease has been supported by high-level evidence and guidelines since 2010, 2,3 shifting management patterns toward more radical prostatectomy in higherrisk disease and away from radiotherapy does not coincide with any new level 1 evidence or guideline changes. 6 The potential downstream effects of efforts to increase AS/WW for men with low-risk disease on management of other risk groups requires further examination. Strengths of this study include the large, diverse population representative of the US population and high-quality AS/WW data, providing an accurate and contemporary metric of AS/WW use and management trends in the United States. Limitations include lack of data on AS/WW compliance and lack of information regarding neoadjuvant androgen deprivation therapy use. Also, the study only investigated management patterns; how the trends will translate into clinical outcomes is unknown. 
